v3.21.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Current Assets:    
Cash and cash equivalents $ 5,637,907 $ 4,401,114
Prepaid research and development 236,882 233,035
Prepaid expenses and other current assets 297,510 501,689
Total Current Assets 6,172,299 5,135,838
Other Assets:    
Research and development supplies 1,548,397
Right-to-use asset 282,630
Acquired in-process research and development 455,000
Goodwill 131,495
Fixed assets, net 30,213
Advance to seller 350,000
Intangible assets, net 5,465 5,606
Total Assets 8,625,499 5,491,444
Current Liabilities:    
Accounts payable 637,400 648,739
Accrued expenses 1,331,449 856,639
Lease liability, current 44,403
Note payable 29,088
Total Current Liabilities 2,042,340 1,505,378
Lease liability, net of current portion 239,505
Contingent liabilities 726,012
Total Liabilities 3,007,857 1,505,378
Commitments and contingencies
Shareholders’ Equity    
Preferred Stock, 5,000,000 shares authorized with a par value of $0.001 per share, 0 shares outstanding at March 31, 2021 and December 31, 2020
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 17,269,877 and 14,393,100 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively 17,270 14,393
Additional paid in capital 41,953,925 35,491,462
Accumulated deficit (36,353,553) (31,519,789)
Total Shareholders’ Equity 5,617,642 3,986,066
Total Liabilities and Shareholders’ Equity $ 8,625,499 $ 5,491,444

Source